BR9810312A - Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico - Google Patents

Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico

Info

Publication number
BR9810312A
BR9810312A BR9810312-1A BR9810312A BR9810312A BR 9810312 A BR9810312 A BR 9810312A BR 9810312 A BR9810312 A BR 9810312A BR 9810312 A BR9810312 A BR 9810312A
Authority
BR
Brazil
Prior art keywords
side effects
reduced side
pharmaceutical composition
derivative
hydroxy acid
Prior art date
Application number
BR9810312-1A
Other languages
English (en)
Inventor
Balazs Sumegi
Original Assignee
Gene Lab Inc N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Lab Inc N filed Critical Gene Lab Inc N
Publication of BR9810312A publication Critical patent/BR9810312A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO FARMACêUTICA QUE APRESENTA ATIVIDADE ANTITUMORAL ACENTUADA E/OU EFEITOS COLATERAIS REDUZIDOS CONTENDO UM AGENTE ANTITUMORAL E UM DERIVADO DO áCIDO HIDROXìMICO"<D>. A invenção refere-se a composições farmacêuticas que apresentam uma atividade antitumoral acentuada ou efeitos colateral(ais) reduzido(s) compreendendo uma substância ativa conhecida que apresenta efeito antitumoral ou um sal aceitável farmaceuticamente da mesma e um derivado do ácido hidroxímico da fórmula (I) ou um sal de adição ácida útil terapeuticamente do mesmo.
BR9810312-1A 1997-06-23 1998-06-22 Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico BR9810312A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity
PCT/IB1998/000961 WO1998058676A1 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative

Publications (1)

Publication Number Publication Date
BR9810312A true BR9810312A (pt) 2000-09-19

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810312-1A BR9810312A (pt) 1997-06-23 1998-06-22 Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico

Country Status (25)

Country Link
US (4) US6440998B1 (pt)
EP (1) EP0993304B1 (pt)
JP (1) JP2002508762A (pt)
KR (1) KR20010020496A (pt)
CN (1) CN1127984C (pt)
AT (1) ATE235918T1 (pt)
AU (1) AU735922B2 (pt)
BR (1) BR9810312A (pt)
CA (1) CA2294913C (pt)
CZ (1) CZ298468B6 (pt)
DE (1) DE69812949T2 (pt)
DK (1) DK0993304T3 (pt)
ES (1) ES2195344T3 (pt)
HK (1) HK1029941A1 (pt)
HU (1) HU9701081D0 (pt)
IL (1) IL133508A (pt)
NO (1) NO322206B1 (pt)
NZ (1) NZ502039A (pt)
PL (1) PL191718B1 (pt)
PT (1) PT993304E (pt)
RU (2) RU2254129C2 (pt)
SK (1) SK282877B6 (pt)
TR (1) TR199903214T2 (pt)
UA (1) UA64757C2 (pt)
WO (1) WO1998058676A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
EP2214789A2 (fr) * 2007-10-30 2010-08-11 Trophos Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN108703970A (zh) * 2013-09-18 2018-10-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
CN1090186C (zh) * 1993-03-31 2002-09-04 麦克公司 治疗aids药物组合物中的hiv蛋白酶抑制剂
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
EP0993304B1 (en) 2003-04-02
ES2195344T3 (es) 2003-12-01
JP2002508762A (ja) 2002-03-19
US6656955B2 (en) 2003-12-02
US20030069270A1 (en) 2003-04-10
RU2214238C2 (ru) 2003-10-20
CA2294913C (en) 2008-12-16
SK282877B6 (sk) 2003-01-09
PT993304E (pt) 2003-08-29
IL133508A (en) 2005-11-20
ATE235918T1 (de) 2003-04-15
RU2254129C2 (ru) 2005-06-20
NZ502039A (en) 2002-03-28
US20030050345A1 (en) 2003-03-13
NO322206B1 (no) 2006-08-28
DE69812949D1 (de) 2003-05-08
UA64757C2 (uk) 2004-03-15
WO1998058676A1 (en) 1998-12-30
AU735922B2 (en) 2001-07-19
SK176499A3 (en) 2000-09-12
US6440998B1 (en) 2002-08-27
US6720337B2 (en) 2004-04-13
TR199903214T2 (xx) 2000-12-21
CN1263471A (zh) 2000-08-16
IL133508A0 (en) 2001-04-30
PL337719A1 (en) 2000-08-28
HK1029941A1 (en) 2001-04-20
PL191718B1 (pl) 2006-06-30
NO996349L (no) 2000-02-23
EP0993304A1 (en) 2000-04-19
US20020147213A1 (en) 2002-10-10
HU9701081D0 (en) 1997-08-28
US6838469B2 (en) 2005-01-04
NO996349D0 (no) 1999-12-20
DK0993304T3 (da) 2003-07-28
AU7783798A (en) 1999-01-04
CN1127984C (zh) 2003-11-19
KR20010020496A (ko) 2001-03-15
CA2294913A1 (en) 1998-12-30
CZ462599A3 (cs) 2000-05-17
DE69812949T2 (de) 2004-02-05
CZ298468B6 (cs) 2007-10-10

Similar Documents

Publication Publication Date Title
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
BR9611802A (pt) Composições farmacêuticas
BR9809468A (pt) Formulações farmacêuticas contendo voriconazol
BRPI9710372B8 (pt) composto, e, composição farmacêutica.
BR9811818A (pt) Uso de um composto, composto, e, composição farmacêutica
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
HU9601846D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
BR9914251A (pt) Formulações orais de liberação sustentada
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
CA2289717A1 (en) Novel therapy for constipation
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
IL153014A0 (en) Barbituric acid analogs as therapeutic agents
RS20100077A (en) Pharamceutically active uridine esters
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
BR9914419A (pt) Terapia para melhoria da percepção
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
HUP0003571A2 (hu) 6,9-Hídkötésű eritromicin-származékok
CA2218766A1 (fr) Composes bicycliques-aromatiques
TR200101633T2 (tr) Farmasötik bileşim
BR0012696A (pt) Composição oftálmica
BR0210744A (pt) Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time